A trial registration posted to ClinicalTrials.gov describes a new University of Southern California study, the Vascular Intervention Strategies Trial for Alzheimer's (VISTA, NCT07447206), as a pharmacist-led feasibility pilot enrolling 10 people age 50 to 75 who carry the APOE e4 gene variant and are considered at risk for dementia. According to the registration, all participants will receive angiotensin receptor blockers for high blood pressure and treatment for high cholesterol, with the study designed to test whether managing these two vascular risk factors is feasible in this population, not to prove the drugs prevent or slow Alzheimer's disease. The APOE e4 variant is the strongest common genetic risk factor for late-onset Alzheimer's disease, and hypertension and high cholesterol are established vascular risk factors linked in prior observational research to higher dementia risk, which is the rationale the registration gives for the design. This is a small feasibility study, the kind of trial that checks whether recruitment, dosing, and follow-up procedures work, and it is explicitly not large or long enough to show whether the interventions change anyone's risk of developing Alzheimer's disease. VISTA joins a body of prior and ongoing research into vascular contributions to Alzheimer's and related dementias, including the multicenter rrAD trial, which tested exercise and intensive vascular risk factor treatment for dementia prevention over two years in older adults, according to a report on that trial's adverse events. That prior work illustrates the broader question VISTA is entering: whether treating vascular risk factors, on top of standard cardiovascular care, measurably slows cognitive decline linked to Alzheimer's disease, a question larger and longer trials, not a 10-person pilot, would be needed to answer.